N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC

Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • ClinicalTrials.gov ID: NCT07823855

Registry updated: 2026-09-16
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).

Interventions

  • hyperfractionated radiotherapy (Radiation)
    simultaneous integrated boost accelerated hyperfractionated radiotherapy

Eligibility criteria

Inclusion Criteria: 1. Age ≥ 18 years, male or female; 2. Histologically or cytologically confirmed high-proliferation non-small cell lung cancer (NSCLC); 3. Assessed by a multidisciplinary team (MDT) and planned to receive thoracic radiotherapy (either curative or palliative), regardless of stage. Exclusion Criteria: 1. Small cell histology; 2. Severe cardiac disease (New York Heart Association \[NYHA\] functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months); 3. Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use effective contraceptive measures; 4. Concurrent participation in other interventional clinical trials; 5. Other conditions deemed by the investigator to make the patient unsuitable for enrollment (e.g., severe mental illness).

Conditions

Non-Small Cell Lung Cancer

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record